First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer
- Conditions
- Metastatic Castration-Resistant Prostate Adenocarcinoma
- Interventions
- Registration Number
- NCT04077021
- Lead Sponsor
- Calibr, a division of Scripps Research
- Brief Summary
CCW702 is an investigational immunotherapy for prostate cancer. This is a two-part, first-in-human study to assess the safety and tolerability of CCW702 administered subcutaneously to patients with metastatic, castration resistant prostate cancer. Part I is divided in to two subparts, in both subparts patients will receive ascending dosages of CCW702 with the goal to determine the maximum tolerated dose (MTD) of CCW702 and efficacious regimen. Part Ia will explore every other other day dosing (QOD); Part Ib will explore weekly dosing (Q7D). In part II of the study, patients will be given the recommended part/phase 2 dose (RP2D) Q7D. The study will also assess the pharmacokinetics and pharmacodynamics of CCW702.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Male
- Target Recruitment
- 22
- Men ≥ 18 years of age at time of informed consent
- For Part 1 and Part 2: men with metastatic castration resistant prostate cancer (mCRPC) with histologically or cytologically confirmed adenocarcinoma of the prostate as defined by one or more of the Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria
- Patients with treated brain metastasis or LMD are eligible if brain imaging shows no evidence of progression
- Must have prostate-specific antigen (PSA) and/or radiographic progression on AT LEAST One novel androgen receptor (AR)-targeted therapy (abiraterone acetate, enzalutamide).
- Eastern Cooperative Oncology Group performance status of 0-1
- Adequate liver function
- Adequate hematopoietic function
- Testosterone level ≤ 50 ng/mL (or 1.73 nmol/L)
- Patient has a life expectancy of greater than 12 weeks
- Patients whose tumors solely exhibit neuroendocrine differentiation or small cell features by histopathology
- Patients with new or progressive brain metastasis or Leptomeningeal Disease (LMD)
- Patients with a history of clinically significant cardiovascular disease such as symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, history of stroke or myocardial infarction within 6 months of enrollment
- Patients with peripheral neuropathy CTCAE Grade >/= 2
- Patients with a known history of hypersensitivity, allergy or intolerance to CCW702 or its excipients
- Patients with untreated or imminent spinal cord compression
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Part 1a: Dose Escalation QOD CCW702 CCW702 administered subcutaneously QOD, dose escalating cohorts. Part 1b: Dose Escalation Q7D CCW702 CCW702 administered subcutaneously Q7D, dose escalating cohorts. Part 2: Dose Expansion CCW702 CCW702 administered subcutaneously Q7D at RP2D.
- Primary Outcome Measures
Name Time Method Part 1a and 1b: Assess the safety and tolerability of CCW702, including incidence of dose limiting toxicities up to day 28 Frequency, severity, duration of treatment-emergent and treatment-related adverse events per CTCAE v5.0
Part 2: to assess clinical efficacy at the RP2D up to 2 years Responses will be measured using prostate cancer working group 3 (PCWG3) criteria
Part 1a and 1b: Select recommended phase/part 2 dose up to 2 years Review of safety and tolerability data (adverse events, dosing) based on CTCAE v5 of all Part 1 subjects/cohorts
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (5)
Johns Hopkins University - Sydney Kimmel Comprehensive Cancer Center
🇺🇸Baltimore, Maryland, United States
Medical College of Wisconsin
🇺🇸Milwaukee, Wisconsin, United States
Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States
University of California at San Diego
🇺🇸San Diego, California, United States
University of Virginia
🇺🇸Charlottesville, Virginia, United States